Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00214_DB01101_nanopub.RAi_WGjVBQNljyaymklH3xibM97TKr8s-Dz_kQzSeeld0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00214_DB01101 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00214_DB01101 label "DDI between Torasemide and Capecitabine - Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed. [drugbank_resource:DB00214_DB01101]" assertion.
- drugbank_resource:DB00214_DB01101 identifier "drugbank_resource:DB00214_DB01101" assertion.
- drugbank_resource:DB00214_DB01101 title "DDI between Torasemide and Capecitabine - Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed." assertion.
- drugbank:DB01101 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB01101 assertion.
- drugbank:DB00214 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB01101 assertion.